Osivax

OVX836 targets seasonal influenza, a disease causing annual global outbreaks and significant mortality.

oligoDOM: A Novel Proprietary Nanoparticles Technology specifically designed to trigger superior T-cell responses, in addition to strong and sustained B-cell responses

Osivax is expanding its oligoDOM based pipeline, with the following candidates: a universal influenza vaccine (OVX836) and coronavirus vaccine (OVX033), as well as a pan-strain human papillomavirus vaccine (PANHPVAX).

Osivax completed enrollment for its Phase 2a clinical trial of the universal influenza vaccine candidate OVX836.

Osivax enrolled the first volunteers in a Phase 2a clinical trial of its universal influenza vaccine candidate, OVX836.

Osivax completed the final visit in its Phase 2a clinical trial of the universal influenza vaccine candidate OVX836.

Osivax offers career opportunities in the development of universal vaccines.

Dr. Nathalie Garçon specializes in vaccinology, immunology, and adjuvant technologies, with experience in research and manufacturing.

Dr. Tim Mosmann directs the human immunology center at the University of Rochester, with expertise in T cell-mediated immunity and cytokine assays.

Prof. Geert Leroux-Roels is an emeritus professor at Ghent University and former director of the Center for Vaccinology (CEVAC).

Prof. Jeffrey Almond studies influenza and vaccine development, including host range determinants in viral evolution.

Osivax aims to develop universal vaccines, starting with OVX836, to reduce the global health burden of influenza and other infectious diseases.

Osivax provides contact details for its offices in Lyon, France, and Angleur, Belgium.

Osivax is developing a new class of universal vaccines empowering both arms of the immune system.